Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Free Cash Flow (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Free Cash Flow for 6 consecutive years, with -$46.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 55.17% to -$46.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$183.9 million, a 57.88% decrease, with the full-year FY2024 number at -$135.1 million, down 71.96% from a year prior.
  • Free Cash Flow was -$46.4 million for Q3 2025 at 4D Molecular Therapeutics, down from -$43.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $301000.0 in Q3 2023 to a low of -$48.4 million in Q1 2025.
  • A 5-year average of -$27.8 million and a median of -$28.1 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: soared 101.31% in 2023, then plummeted 10036.21% in 2024.
  • 4D Molecular Therapeutics' Free Cash Flow stood at -$29.6 million in 2021, then rose by 21.37% to -$23.3 million in 2022, then dropped by 16.17% to -$27.1 million in 2023, then crashed by 68.7% to -$45.7 million in 2024, then dropped by 1.6% to -$46.4 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Free Cash Flow are -$46.4 million (Q3 2025), -$43.4 million (Q2 2025), and -$48.4 million (Q1 2025).